长春瑞滨加顺铂治疗48例晚期非小细胞肺癌

Vinorelbine plus cisplatin in the treatment of 48 cases with advanced non-small-cell lung cancer

目的 :观察长春瑞滨加顺铂联合化疗治疗晚期非小细胞肺癌的临床疗效。方法 :48例Ⅲ—Ⅳ期非小细胞肺癌 (2 2例初治、2 6例复治 ) ,采用长春瑞滨 2 5mg/m2 ,静注 ,第 1,5天 ,顺铂 35mg/m2 ,静注 ,第 1— 3天 ,联合化疗。结果 :初治 2 2例中CR +PR 14例 ,有效率 6 3.6 % ,复治 2 6例中CR +PR 10例 ,有效率 38.5 % ,总有效率5 0 %。中位缓解期 5 .5个月 ,中位生存期 11个月。主要副反应为骨髓抑制及静脉炎 ,采用深静脉给药可减轻静脉炎发生。结论 :长春瑞滨加顺铂联合化疗治疗晚期非小细胞肺癌疗效较高 ,副反应可耐受 ,值得临床进一步观察。

Purpose:To evaluate the efficacy of NP regimen (NVB and DDP) in advanced non-small-cell lung cancer (NSCLC). Methods:48 patients with advanced NSCLC were treated by NP regimen. All of them had stage Ⅲ-Ⅳ disease (22 of them were primary treatment, the others were subsequent treatment). The chemotherapy dosage of NVB was 25 mg/m2 iv. d1,5, That of DDP was 35 mg/m2 iv d1,3.Results:The overall response rate (RR) was 50%, medium response time 5.5 months, medium survival time 11 months. The RR of 22 patients with primary treatment was 63.6%. The other patients after multiple course therapy 38.5%. The major adverse effects were myelosuppression and vein inflammation drug infusion through deep vein could avoid the vein inflammation. Conclusions:Authors suggest that NP regimen is effective therapy for non-small-cell lung cancer and deserves further clinical observation.